Beigene Ltd., of Waltham, Mass., part of Beigene Co. Ltd., of Beijing, named Eric Hedrick interim chief medical officer. Hedrick has been a clinical advisor to the company since June 2015. He was previously chief medical officer at Epizyme Inc., and vice president of oncology development and interim chief medical officer at Pharmacyclics Inc., where he was involved in the development of ibrutinib. Hedrick has an M.D. from the University of Maryland School of Medicine.